Rocket Pharmaceuticals Withdraws FDA Application for Rare Blood Disease Gene Therapy
Rocket Pharmaceuticals has withdrawn its FDA application for RP-L102, a gene therapy for Fanconi anemia, a rare blood disorder.
The decision follows a company restructuring and pipeline reprioritization focusing on programs with clearer regulatory and commercial pathways.
Rocket will consider external partnerships to potentially advance RP-L102 in the future.